Mutation profile of patients with DLBCL. (A) Relationship between oncogenic mutations and IPI risk groups. (B) Mantel-Haenszel χ2 of oncogenic mutations according to the IPI. (C) Relationship between oncogenic mutations and age. (D) Relationship between oncogenic mutations and Ann Arbor stage. (E) Relationship between oncogenic mutations and extranodal involvement. (F) Relationship between oncogenic mutations and LDH ratio. (G) Relationship between oncogenic mutations and ECOG performance status (PS); ∗P < .05, ∗∗P < .01, ∗∗∗P < .001, and ∗∗∗∗P < .0001.